Rationale and Design for LEGATO-HD Study: A Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0, and 1.5 mg/day) as Treatment in Patients with Huntington Disease

R Reilmann, S Tabrizi, B Leavitt, JC Stout, P Piccini, KE Anderson, A Feigin, M Hayden, M Grozinski-Wolff, E Eyal, S Papapetropoulos

Research output: Contribution to conferencePosterpeer-review

Original languageEnglish
Number of pages2
Publication statusPublished - Jan 2016
EventNinth Annual Huntington Disease Clinical Research Symposium - Grant Hyatt , Tampa Bay, United States of America
Duration: 24 Oct 201524 Oct 2015
Conference number: 9th


WorkshopNinth Annual Huntington Disease Clinical Research Symposium
Country/TerritoryUnited States of America
CityTampa Bay

Cite this